

For further information please contact:

Ellen Fuerst (Public Relations)
Cenix BioScience GmbH
Tel. +49 (351) 4173-128
fuerst@cenix-bioscience.com



CENIX BIOSCIENCE MOVES INTO NEW, STATE OF THE ART FACILITIES IN DRESDEN'S BIO-INNOVATION CENTER

Dresden, Germany – May 17, 2004. Cenix BioScience, the premier specialist in advanced RNAi research services, today announced that it has now moved all operations into brand new facilities within Dresden's recently completed BioInnovation Center (BIOZ).

Cenix BioScience offers premium research services combining genome-driven high throughput applications of RNA interference (RNAi) with high content readout methodologies in human cells, *Drosophila* and *C. elegans* to accelerate and improve the quality of drug discovery in diverse disease areas.

For the last 3 years, all operations have been housed within Dresden's Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG), one of Cenix's parent institutes along with the European Molecular Biology Laboratory (EMBL) in Heidelberg, where Cenix started work in October 2000. The new location, which offers over 800 square meters of fully customized facilities in the BIOZ, will provide ample space for Cenix's rapidly expanding RNAi-related research services.

"The opportunity to grow-up and mature as a company within the MPI-CBG has been an exceptional privilege and a true joy, for which we at Cenix are very thankful", said Dr. Christophe Echeverri, CEO and CSO of Cenix BioScience. "The completion of our more permanent home within the Dresden BioInnovation Center comes at a perfect time for Cenix, as the fast-growing demand for our RNAi research services now calls for larger facilities. The new location is only 2 blocks away from the MPI-CBG, so we look forward to maintaining our existing tight contacts there and also adding an important new dimension to the growing life science research landscape in Dresden."

The move of all operations incurred only one day of "down time", thus insuring that ongoing projects were minimally affected, if at all. The contact details for the new Cenix operations are as follows:

Cenix BioScience GmbH
Tatzberg 47
01307 Dresden, Germany
Tel. +49 (351) 4173 0
Fax +49 (351) 4173 109
www.cenix-bioscience.com

About Cenix BioScience

Cenix BioScience is a specialist in advanced RNAi research services, offering high throughput genomic RNAi for all scopes of target discovery and validation projects. As the first biotech company to focus exclusively on high throughput (HT) RNAi, Cenix offers over 5 years of specialized experience developing and applying HT-RNAi in a wide range of human cells as well as *Drosophila* and *C. elegans*. Cenix has accumulated unparalleled depth and breadth of experience in this field, combining proprietary siRNA libraries with high content phenotypic analyses to accelerate discovery and validation programs in a variety of disease indications. For more information, please visit www.cenix-bioscience.com.